Lupus clinical trials in Illinois
14 studies for Lupus are looking for participants at sites in Illinois.
Cities in Illinois
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
RecruitingPhase 3
Ages 16 and older · All sexes · Updated Oct 2, 2026 · NCT06617325Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Oct 1, 2026 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 30, 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07607964A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
RecruitingObservational study
Ages 16 and older · All sexes · Updated Sep 3, 2026 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 10, 2026 · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Apr 15, 2026 · NCT05934149From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.